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ABSTRACT 
Objective: 
The objective of this study was to evaluate adherence and causes for non-adherence to 
antihypertensive therapy in Austrian patients. A special focus was laid on social 
parameters and behavioural theories. 
 
Methods: 
Patients were invited via advertisements in community pharmacies in Austria to 
complete an online survey. Inclusion criteria were an age of 18 years or older, a 
diagnosis of arterial hypertension and a current prescription of antihypertensive 
medication. Adherence was measured by the 4-item Morisky scale. Non-adherence was 
defined by at least one point in the Morisky scale. Several demographic, social and 
behavioural parameters were analysed as potential co-variables associated with 
adherence. 
 
Results: 
323 patients completed the online survey of which 109 (33.7%) met the criteria for non-
adherence. In a multivariable model self-efficacy and age were associated with 
adherence, whereas intention and barriers were linked to non-adherence. 56 patients 
(17.3%) were classified as intentionally non-adherent. 
 
Conclusion: 
This study demonstrates that non-adherence affects an important proportion of patients 
in the treatment of arterial hypertension. Young age was a particularly important risk 
factor for non-adherence and this patient population is therefore in need of special 
attention. Modifiable risk factors were identified which could help improving the 
treatment of arterial hypertension and potentially other chronic conditions. 
 ZUSAMMENFASSUNG 
Ziel: 
Das Ziel dieser Studie war die Erhebung der Therapieadhärenz bei Patienten mit 
arteriellem Bluthochdruck in Österreich, und deren Ursachen, mit besonderem 
Augenmerk auf sozialen Parametern und behavioralen Theorien  
Methoden: 
Patienten wurden in öffentlichen Apotheken an Hand von Postern und anderem 
Informationsmaterial zum Ausfüllen eines Online-Fragebogens eingeladen. 
Eingeschlossen wurden Patienten ab einem Mindestalter von 18 Jahren, mit 
Bluthochdruckerkrankung und einer aktuellen Verschreibung von antihypertensiven 
Medikamenten. Die Adhärenz wurde mit Hilfe der 4-teiligen Morisky Skala gemessen. Ab 
einer bejahend beantworteten Frage galt der Patient als nicht adhärent. Weiters wurden 
demographische, soziale und behaviorale Parameter erhoben, um deren Zusammenhang 
mit Therapieadhärenz zu untersuchen. 
Resultate: 
323 Patienten konnten rekrutiert werden, wovon 109 (33.7%) als nicht adhärent 
klassifiziert wurden. In einem multivariablen Model zeigten sich „self-efficacy“ und Alter 
mit Adhärenz verbunden, während „intention“ und „barriers“ mit fehlender Adhärenz 
assoziiert waren. 56 Patienten (17.3%) wurden als absichtlich nicht-adhärent 
klassifiziert. 
Fazit: 
Diese Studie zeigt, dass mangelhafte Adhärenz ein gewichtiges Problem in der Therapie 
von Bluthochdruckerkrankungen darstellt. Besonders bei jungen Menschen scheint die 
Therapie-Adhärenz schlecht zu sein. Es konnten jedoch auch modifizierbar 
Risikofaktoren identifiziert werden. Zukünftige Studien sollten sich auf die Entwicklung 
und Evaluierung von Interventionen konzentrieren, die diese Risikofaktoren 
beeinflussen. 
 INTRODUCTION 
Over the last decades important progress in medical and pharmaceutical sciences led to 
the development of new efficacious treatments for diverse chronic conditions. However, 
the ultimate impact of any drug treatment – often measured as the effectiveness – also 
depends on the patients’ adherence to it. Treatments with high efficacy in clinical trials 
may turn out to be only moderately effective due to incomplete compliance with 
recommended dosing regimens in real world settings. Non-adherence was therefore 
identified as a major public health problem by constituting a barrier to the effective, safe 
and cost-effective use of drugs (1). Conclusively, the World Health Organization (WHO) 
reported non-adherence as a worldwide medical problem associated with excess 
morbidity, mortality and unnecessary costs (2). WHO defines adherence “as the extent 
to which a person’s behaviour – taking medication, following a diet, and/or executing 
lifestyle changes – corresponds with agreed recommendations from a health care 
provider” (2). In arterial hypertension - defined as a systolic blood pressure of 
140mmHg or above and / or a diastolic blood pressure of 90mmHg or above - lack of 
compliance and non-adherence to prescribed medicines is a major reason for 
unsatisfying therapeutic outcomes and therefore a major challenge (3). Similar to other 
chronic conditions including diabetes and overweight, a main reason for problems in 
patients’ adherence is the asymptomatic nature of the disease. Other previously 
reported factors contributing to non-adherence include the long-term disease course of 
hypertension and thus the necessity for lifelong treatment and multiple daily dosing (4, 
5). 
Improving the adherence to therapeutic regimens could substantially improve 
therapeutic outcomes especially in high-income countries, where effective drugs are 
widely available for everybody. It may prove most cost effective to increase the 
effectiveness of already licensed drugs by improving patient adherence rather than 
focussing on developing ever new therapeutic products. A better understanding of 
causes of non-adherence is however necessary to ultimately improve effectiveness of 
current drugs. Thus, the aim of this study was to evaluate adherence to long-term 
medication in Austria and determine its causes with a special focus on social parameters 
and behavioural theories. 
 
METHODS 
Data presented in this article stem from the European Union funded project 
“Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use 
of medicines in Europe” (ABC). Cumulative data for the entire European cohort were 
published in June 2012 in the Final Study Report of the ABC Project and in “Value in 
Health” (in press). This manuscript describes in detail findings of this survey restricted 
to Austria. 
Patients were recruited via advertisements (posters and printed material) in community 
pharmacies across Austria, which were randomly selected from a list provided by the 
national prescription pricing authority. 1272 pharmacies were contacted. Patients were 
eligible if they were 18 years of age or older, had a diagnosis of arterial hypertension, 
were currently prescribed medication against arterial hypertension and were self-
responsible for drug-administration. Exclusion criteria were lack of consent, presence of 
a self-reported psychiatric condition and living in a nursing home or similar facility. The 
questionnaire was completed via a web-based survey tool provided by 
SurveyMonkey.com. 
 
Measuring Adherence 
In this study, adherence was measured by the 4-item Morisky Medication Adherence 
Scale (MMAS-4). The MMAS-4 is the most frequently used questionnaire measuring 
adherence to medication. This scale, originally designed to evaluate medication 
adherence in hypertensive patients, has been validated and was found to be reliable in a 
variety of medication adherence studies (6, 7). 
Patients were categorized as non-adherent if they answered one or more question of the 
MMAS-4 with “yes”. They were classified as intentionally non-adherent when either item 
3 or 4 or both were answered with “yes” (see also table 1). The MMAS-4 is shown in 
table 2. 
 
Measurement of variables & instruments used 
The Stanford Self-Rated Health Scale was used to measure health status; the Revised Life 
Orientation Test (LOT-R) was used to determine optimism (8); the Beliefs about 
Medicines Questionnaire (BMQ-S11) was applied to evaluate beliefs about medicine (9); 
to measure attitudes, normative beliefs, barriers, facilitators, intention and self-efficacy, 
a theory of planned behaviour (TPB) questionnaire was used. TPB is a theory in 
psychology about the link between beliefs and behaviour (10). A questionnaire of the 
European Task Force on Patient Evaluation in General Practice (EUROPEP) was used to 
measure satisfaction with the practitioner and her / his practice (11); the Building 
Research Initiative Group: Chronic Illness Management and Adherence in 
Transplantation (BRIGHT) for barriers and social support (12, 13) and the Brief Illness 
Perception Questionnaire (BIPQ) were applied to assess parameters of illness-
perception (14). 
 
Ethical Considerations 
Ethical approval was obtained by the national ethics committee in Austria (590/2011). 
Participants provided informed consent by checking a box in the online survey to 
confirm that they had read and understood all participant information. Access to the 
survey was denied if the box was not checked. SurveyMonkey®, where the 
questionnaire responses were stored initially, guaranteed data safety. SurveyMonkey® 
has signed up to the Safe Harbor agreement. This agreement was created to enable the 
transfer of ‘personal data’ between the EU and USA following the introduction of the 
EU’s Data Protection Directive (1995). SurveyMonkey® was asked in written to 
completely delete survey data from its servers after the termination of the survey. 
 
Data analysis 
The primary outcome of this study was the estimation of the percentage of non-
adherent patients defined as patients having answered "yes" to at least one of the 4 
items of the Morisky questionnaire. For binominal variables a Fisher’s test were applied 
to calculate differences in distribution between adherent and non-adherent patients. For 
continuous variables, a Mann-Whitney test was computed. Binary logistic regression 
analysis was performed to compute a multivariate model including parameters with a 
significant difference in distribution between adherent and non-adherent patients. 
Complete case analysis was used. 95% confidence intervals were derived using the 
normal approximation of the binomial distribution. Statistical analysis was performed 
with “R”, version 3.0.2. 
 
 
RESULTS 
323 participants completed the questionnaire. 178 (55.1%) were men and 145 (44.9%) 
women. Median age was 62 years (25th-75th percentile: 51-69y; range: 25-89y). For 
more demographic data see table 2. 
In the overall study population, 109 (33.7%) had a Morisky-score of 1 or more and were 
therefore classified as non-adherent. 56 patients (17.3%) were classified as intentionally 
non-adherent. 
 
Factors influencing non-adherence 
In univariable analysis, young age was associated with non-adherence. The rate of non-
adherence was also significantly higher in working patients or students compared to 
retired or unemployed ones. Conversely, adherent patients were prescribed a higher 
number of different drugs (p = 0.001), tablets per day (p = 0.008) and had more items on 
the last prescription (p = 0.028). 
Patients classified as adherent had a high score in the necessity section of the Beliefs 
About Medicine Questionnaire, the attitude, normative beliefs, intention and self efficacy 
section of the Theory of Planned Behaviour Questionnaire and the illness consequences 
(i.e. “How much does your illness affect your life?”), illness timeline (i.e. “How long do 
you think your illness will continue?”), personal control (i.e. “How much control do you 
feel you have over your illness?”), treatment control (i.e. “How much do you think your 
treatment can help your illness?”) and illness coherence (i.e. “How well do you feel you 
understand your illness?”) part of the BIPQ. Satisfaction with the treating practitioner 
and his practice were significantly higher in adherent patients. In contrast, the use of 
cost coping strategies and a high score in the barriers-section of the BRIGHT 
questionnaire were associated with non-adherence. 
In a multivariable model, older age (OR 0.94; 95% CI 0.89 – 0.99; p = 0.02) and self-
efficacy (i.e. the personal sense of control; TPB) (OR 0.66; 95% CI 0.52 – 0.83; p < 0.001) 
were associated with adherence, whereas intention (TPB) (OR 1.44; 95% CI 1.04 – 2.16; 
p=0.04) and barriers (BRIGHT) (OR 1.11; 95% CI 1.02 – 1.23; p=0.02) were linked to 
non-adherence (see table 3). 
 
Intentional non-adherence 
Intentional non-adherence was significantly more frequent in participants reporting 
regular employment or students than in retired or unemployed. (15.0% vs. 33.7%; p = 
0.01). Use of cost coping strategies was associated with intentional non-adherence 
(Mann-Whitney-U: p = 0.048). Scores in the variables attitudes, intention, self-efficacy 
and normative believes (TPB) and illness timeline (i.e. people think that their illness will 
continue for a long time) and treatment control (i.e. people think that treatment can help 
the illness) (BIPQ) were lower in patients classified as intentionally non-adherent. Also a 
high score in barriers (BRIGHT) was significantly associated with intentional non-
adherence. Due to the small case numbers, multivariable analysis was omitted. 
  
DISCUSSION 
Non-adherence to antihypertensive medication was 33.7% in our patient population. 
These data are therefore proof of an important potential for improvement of patient 
care even in high-income countries, where universal access to healthcare is guaranteed. 
The observed proportion is considerably higher than for other medical conditions with a 
more symptomatic disease course including multiple sclerosis or follow-on therapy after 
acute coronary syndrome (15, 16). However, other European countries had 
considerably higher proportions of non-adherence accounting for up to 70% of patients 
in Hungary (17). 
In our multivariable analysis we identified four risk factors significantly influencing the 
adherence to antihypertensive medication.  
Young age was shown to be linked to non-adherence. Although this is a per-se non-
modifiable factor, young patients may require special counselling to improve adherence. 
This may be of particular importance because young patients are most likely to benefit 
from improved adherence to antihypertensive drugs. 
Among the modifiable risk factors low “self-efficacy” (TPB), high intention (TPB) and 
high barriers (BRIGHT) were identified as predictors for non-adherence. Self-efficacy is 
the personal sense of control and its crucial importance in several different settings was 
shown previously (18-20). People who believe their action can solve a problem become 
more inclined to do so and feel more committed to their decisions (21). It can be 
influenced by a person’s own experience, the experiences of others, social persuasion 
and someone’s psychological status(22). Also barriers including side effects of drugs or 
forgetfulness should be specifically addressed in all patients with hypertension to 
optimize therapeutic outcomes. This also shows that personal beliefs and social 
influences are more important for adherence than the clinical situation or factors 
attributable to the disease itself. Paradoxically, we also found high intention to be 
predictive for non-adherence. This finding stands in contrast to literature(23) and we 
speculate that it might be an artefact of statistical analyses, especially because intention 
was already very high in the overall study population (median 10 out of 10 points). 
Our results also show the crucial role of allowing enough time in personal 
communications between the practitioner and patients to make interventions possible 
and successful. Such risk factors can be influenced by a range of interventions. Self-
efficacy might be increased by programs such as the herz.leben program, which was 
established in Styria, Austria. It provides structured training for patients on several 
aspects of the treatment and control of the disease (e.g. adequate nutrition, physical 
exercise, blood measurement training) and was shown to significantly decrease blood 
pressure and the risk of a cardiovascular event.(24) 
 
Limitations of this study included the way of data acquisition possibly leading to a 
selection bias in the study population. Questionnaires and responses were provided via 
internet leading to the impossibility to confirm diagnoses or responses. Importantly, 
patient groups without internet access were most likely underrepresented in this 
survey. The so-called self-serving bias, defined as the distortion of cognition of 
perception in order to maintain self-esteem, might have confounded our results and the 
impact of non-responders was not assessable during this survey. However, the 
anonymity of this survey may also be regarded as strength as responders are less likely 
to conceal non-adherence compared to personal interviews.  
In summary this study reports a high proportion of non-adherence to antihypertensive 
medication in Austria, but identifies modifiable variables influencing adherence. This 
survey may provide important insights for the treatment of arterial hypertension and 
other chronic conditions. Future studies should evaluate specific interventions to 
improve adherence to therapeutic regimens. This could help to ameliorate effectiveness 
and efficiency of existing drugs. 
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 Table 1: The Morisky 4-Item Self-Report MEASURE of Medication-taking behaviour (MMAS-4) 
 Yes No 
1. Do you ever forget to take your high blood pressure medicine? 0 1 
2. Do you ever have problems remembering to take your high blood 
pressure medicine? 
0 1 
3. When you feel better, do you sometimes stop taking your high blood 
pressure medicine? 
0 1 
4. Sometimes if you feel worse when you take your high blood pressure 
medicine, do you stop taking it? 
0 1 
 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required.  A Licensure agreement 
is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, 
UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, 
dmorisky@ucla.edu. 
 
 
Table 2: Demographic data and missing data for overall study population (n=323) 
Variable (% missing data) median (25
th
 – 75th percentile) or absolute 
numbers (% of overall population) 
Age (0%) 62y (51-69y) 
Sex (0%) 
male 
female 
 
178 (55.1%) 
145 (44.9%) 
Civil Status (2.2%) 
Married 
Single/divorced/widow 
 
209 (64.7%) 
107 (33.1%) 
Education (2.8%) 
Primary / secondary 
Higher than primary / secondary 
 
120 (37.2%) 
194 (60.1%) 
Employment (1.5%) 
Working / Student 
Retired / Unemployed 
 
119 (36.8%) 
199 (61.6%) 
Number of medical conditions, median (1.2%) 2 (1-3) 
Number of medicines, median (1.2%) 4 (2-6) 
Number of tablets per day, median (2.8%) 4 (2-7) 
Dosage frequency (0.9%) 
Once daily 
Two times daily 
Three times daily 
> three times daily 
 
114 (35.3%) 
110 (34.1%) 
96 (29.7%) 
0 (0%) 
Self reported health status (0.6%) 
Poor 
Fair 
Good 
Very good / excellent 
 
23 (7.1%) 
96 (29.7%) 
128 (39.6%) 
74 (22.9%) 
Number of items on last prescription, median (8.7%) 4 (2-6) 
Do you pay for prescription (0.9%) 
No 
Yes, prescription charge 
Yes, full cost 
 
26 (8.0%) 
282 (87.3%) 
12 (3.7%) 
Affordability problem (0.9%) 
No 
Yes 
 
231(71.5%) 
89 (27.6%) 
Use of cost coping strategies, mean (3.1%) 0.9585 
Optimism – life orientation test (0= low, 24=high) (9.0%) 15 (13-18) 
Necessities of medicines (5=low, 25=high) (8.6%) 19 (16.75-22) 
Concerns about medicines (6=low, 30=high) (10.8%) 15 (12-19) 
Attitudes – theory of planned behaviour (7=low, 
35=high) (12.3%) 
28 (25-32) 
Normative beliefs - theory of planned behaviour (3=low, 
15=high) (12.3%) 
15 (12-15) 
Barriers – theory of planned behaviour (1=low, 5=high) 
(10.2%) 
1 (1-3.75) 
Facilitators – theory of planned behaviour (3=low, 
15=high) (13.6%) 
8 (5-11) 
Intention – theory of planned behaviour (2=low, 
10=high) (10.2%) 
10 (9-10) 
Self efficacy – theory of planned behaviour (2=low, 8 (6-10) 
 
 
 
10=high) (7.4%) 
Practitioner (7.4%) 
General practitioner / family physician 
Other 
 
163 (50.5%) 
136 (42.1%) 
Gender of practitioner (10.2%) 
Female 
Male 
 
114 (35.3%) 
176 (54.5%) 
EUROPEP satisfaction with practitioner (17=low, 
85=high) (18.9%) 
70 (62-79) 
EUROPEP satisfaction with practice (6=low, 30=high) 
(16.1%) 
24 (21-29) 
BRIGHT barriers (0=low, 60=high) (45.8%) 5 (1-8.5) 
BRIGHT social support (0=low, 28=high) (13.0%) 2 (0-4) 
BIPQ 
Illness consequences (8.0%) 
Illness timeline (8.7%) 
Personal control (8.0%) 
Treatment control (9.0%) 
Identity (9.6%) 
Concern about illness (9.3%) 
Illness coherence (10.8%) 
Emotional representations (9.6%) 
 
5 (2-8) 
10 (8-10) 
7 (4-8) 
9 (7-10) 
5 (2.75-7) 
5 (3-8) 
8 (6-10) 
4 (2-6) 
Income (11.5%) 
Salaries / wages 
Pensions / benefits / others 
 
93 (28.8%) 
193 (59.8%) 
Total Income (deciles) (9.0%) 
1-4 
5-7 
8-10 
Not willing to provide 
 
96 (29.7%) 
103 (31.9%) 
57 (17.6%) 
38 (11.8%) 
Income perception (8.0%) 
Comfortable 
Coping 
Difficult / very difficult 
Not willing to provide 
 
65 (20.1%) 
141 (43.7%) 
54 (16.7%) 
37 (11.5%) 
Ease of borrowing (8.7%) 
Very difficult, quite difficult 
Neither easy nor difficult 
Quite easy, very easy 
Not willing to provide 
 
122 (37.8%) 
85 (26.3%) 
38 (11.8%) 
50 (15.5%) 
 
Table 3: Multivariable model investigating association between various variables and non-adherence 
Variable OR 95% CI p-value 
Age 0.94 0.89 – 0.99 0.022 
Number of medicines 0.93 0.67 – 1.25 0.622 
Number of tablets per day 1.00 0.85 – 1.13 0.983 
Employment status 1.96 0.56 – 7.32 0.299 
Number of medical conditions 0.96 0.64 – 1.37 0.829 
Use of coping strategies 0.95 0.77 – 1.14 0.619 
Necessities (BMQ) 0.92 0.79 – 1.07 0.303 
Attitudes (TPB) 0.97 0.88 – 1.08 0.620 
Normative believes (TPB) 0.94 0.79 – 1.11 0.458 
Self efficacy (TPB) 0.66 0.52 – 0.83 <0.001 
Intention (TPB) 1.44 1.04 – 2.16 0.044 
Illness consequences (BIPQ1) 0.91 0.77 – 1.08 0.282 
Illness timeline (BIPQ2) 0.95 0.74 – 1.21 0.661 
Personal control (BIPQ3) 0.99 0.82 – 1.19 0.897 
Treatment control (BIPQ4) 1.08 0.80 – 1.46 0.614 
Illness coherence (BIPQ7) 0.92 0.75 – 1.12 0.395 
Satisfaction of practitioner 1.03 0.97 – 1.09 0.399 
Satisfaction with practice 1.05 0.91 – 1.22 0.486 
Barriers (BRIGHT) 1.12 1.02 – 1.23 0.025 
     
 
 
 
 
